Evidence map›Paper›PMID 28455446›Full record

ArticleThe Journal of biological chemistry2017

Enterovirus 71 suppresses interferon responses by blocking Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling through inducing karyopherin-α1 degradation.

Chunyang Wang, Menghuai Sun, Xinhui Yuan, Lianfu Ji, Yu Jin, Carol J Cardona, Zheng Xing

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 66 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Current status of hand-foot-and-mouth disease.Journal of biomedical science · 2023
    Review
  14. Article
  15. Phosphorylation of enteroviral 2AJournal of medical virology · 2023
    Article
  16. Review
  17. Potential therapeutic effects of Ivermectin in COVID-19.Experimental biology and medicine (Maywood, N.J.) · 2022
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Chunyang WangFrom the Medical School and Jiangsu Provincial Key Laboratory of Medicine, Nanjing University, Nanjing 210008, China.
Menghuai SunFrom the Medical School and Jiangsu Provincial Key Laboratory of Medicine, Nanjing University, Nanjing 210008, China.
Xinhui YuanFrom the Medical School and Jiangsu Provincial Key Laboratory of Medicine, Nanjing University, Nanjing 210008, China.
Lianfu JiFrom the Medical School and Jiangsu Provincial Key Laboratory of Medicine, Nanjing University, Nanjing 210008, China.
Yu JinFrom the Medical School and Jiangsu Provincial Key Laboratory of Medicine, Nanjing University, Nanjing 210008, China, jinyuldyy@163.com.
Carol J Cardonathe Department of Veterinary Biomedical Sciences, College of Veterinary Medicine, University of Minnesota at Twin Cities, St. Paul, Minnesota 55108.
Zheng XingFrom the Medical School and Jiangsu Provincial Key Laboratory of Medicine, Nanjing University, Nanjing 210008, China, zxing@umn.edu zxing@nju.edu.cn.
Nanjing Children's Hospital · CNNanjing Medical University · CNUniversity of Minnesota · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enterovirus 71 (EV71) has emerged as one of the most important enteroviruses since the eradication of poliovirus, and it causes severe neurological symptoms for which no effective antiviral drugs are available. Type I interferons (IFN) α/β have been used clinically as antiviral therapy as the first line of defense against virus infections successfully for decades. However, treatment with type I interferons has not been effective in patients with EV71 infection. In this study, we found that in cells pretreated with IFN-β, EV71 infection could still lead to a cytopathic effect, and the viral replication was not affected. The mechanism by which EV71 antagonizes interferon signaling, however, has been controversial. Our study indicated that EV71 infection did not inhibit phosphorylation of STAT1/2 induced by IFN-β stimulation, but p-STAT1/2 transport into the nucleus was significantly blocked. We showed that EV71 infection reduced the formation of STAT/karyopherin-α1 (KPNA1) complex upon interferon stimulation and that the virus down-regulated the expression of KPNA1, a nuclear localization signal receptor for p-STAT1. Using specific caspase inhibitors and siRNA for caspase-3, we demonstrated that EV71 infection induced degradation of cellular KPNA1 in a caspase-3-dependent manner, which led to decreased induction of interferon-inducible genes and IFN response. Viral 2A and 3C proteases did not degrade KPNA1, inhibit the activity of ISRE or suppress the transcription of interferon-inducible genes induced by IFN-β. Our study demonstrates a novel mechanism by which antiviral signaling is suppressed through degradation of KPNA1 by activated caspase-3 induced in an enteroviral infection.

Indexed as

Signal TransductionActive Transport, Cell Nucleusalpha KaryopherinsAnimalsCaspase 3Chlorocebus aethiopsEnterocytesEnterovirus A, HumanHeLa CellsHT29 CellsHumansInterferon-betaJanus Kinase 1PhosphorylationProtein Processing, Post-TranslationalProteolysisalpha KaryopherinsCASP3 protein, humanCaspase 3Interferon-betaJAK1 protein, humanJanus Kinase 1KPNA1 protein, humanRecombinant Fusion ProteinsSTAT1 protein, humanSTAT1 Transcription FactorSTAT2 protein, humanSTAT2 Transcription FactorinterferonJanus kinase (JAK)protein expressionRNA virusSTAT transcription factor

Identifiers

PMID28455446
PMCPMC5473229
OpenAlexW2609669866

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.